Further trial for Anika's Orthovisc underway in US:
This article was originally published in Clinica
Anika Therapeutics has begun a further a Phase III clinical trial of its treatment for osteoarthritic knees, under an investigational device exemption from the US FDA. The Woburn, Massachusetts-based company failed to win US approval for the product last year due to insufficient data from its initial study. Orthovisc, an injectable hyaluronic acid-based product for restoring the elasticity and viscosity of synovial fluid, will be evaluated in around 350 patients at 20 sites in both Canada and the US.